Modulo Bio is a San Diego, CA-based biotech that models the neuroimmune system to identify drug candidates targeting microglia. Its proprietary Modulo Neuroimmune Platform integrates software, automation, and artificial intelligence with advances in stem cell biology and neuroscience to generate an AI-generated neuroimmune fingerprint of disease. Research starts with patients, leveraging stem cell technology to generate brain cells from patients with different diseases. The company has identified novel microglia targets and generated candidate therapeutics that the company says offer the promise of effective treatments for diseases like ALS and FTD. Modulo intends to use the funds to accelerate development of its first therapeutic program and its Modulo Neuroimmune Platform. Leadership includes CEO Michael Horowitz, Scott Patterson, and Justin Ichida, PhD.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2023